Seattle Genetics is conducting an ongoing pivotal trial of brentuximab vedotin for relapsed and refractory Hodgkin lymphoma. The trial is being conducted under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA), and top-line data are planned in the second half of 2010. In addition, the company is conducting an ongoing phase II trial for relapsed and refractory systemic anaplastic large cell lymphoma and a phase II retreatment trial for relapsed patients who previously responded to brentuximab vedotin therapy. The company also plans to initiate a phase III relapse prevention trial for post-transplant Hodgkin lymphoma patients in the first half of 2010.

Seattle Genetics is developing brentuximab vedotin in collaboration with Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company, under which Seattle Genetics has U.S. and Canadian commercialization rights and Millennium has rights to commercialize brentuximab vedotin in the rest of the world. Seattle Genetics and Millennium are jointly funding worldwide development costs for brentuximab vedotin on a 50:50 basis.

SOURCE Seattle Genetics and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company